Once a reference medicinal product, within the meaning of 5° of Article L. 5121-1, or a reference biological medicinal product, within the meaning of 15° of the same Article, is covered by a compassionate prescribing framework, medicinal products from the same generic group or the same similar biological group authorised after the compassionate prescribing framework was established are deemed to be covered by the compassionate prescribing framework. The holder of the marketing authorisation for the generic medicinal product or similar biological medicinal product or the company authorised to operate it for this purpose are bound by the obligations resulting from this framework and, where applicable, the therapeutic use and patient monitoring protocol.